BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 25344522)

  • 1. Validation of cytogenetic risk groups according to International Prognostic Scoring Systems by peripheral blood CD34+FISH: results from a German diagnostic study in comparison with an international control group.
    Braulke F; Platzbecker U; Müller-Thomas C; Götze K; Germing U; Brümmendorf TH; Nolte F; Hofmann WK; Giagounidis AA; Lübbert M; Greenberg PL; Bennett JM; Solé F; Mallo M; Slovak ML; Ohyashiki K; Le Beau MM; Tüchler H; Pfeilstöcker M; Nösslinger T; Hildebrandt B; Shirneshan K; Aul C; Stauder R; Sperr WR; Valent P; Fonatsch C; Trümper L; Haase D; Schanz J
    Haematologica; 2015 Feb; 100(2):205-13. PubMed ID: 25344522
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular cytogenetic monitoring from CD34+ peripheral blood cells in myelodysplastic syndromes: first results from a prospective multicenter German diagnostic study.
    Braulke F; Jung K; Schanz J; Götze K; Müller-Thomas C; Platzbecker U; Germing U; Brümmendorf TH; Bug G; Ottmann O; Giagounidis AA; Stadler M; Hofmann WK; Schafhausen P; Lübbert M; Schlenk RF; Blau IW; Ganster C; Pfeiffer S; Shirneshan K; Metz M; Detken S; Seraphin J; Jentsch-Ullrich K; Böhme A; Schmidt B; Trümper L; Haase D
    Leuk Res; 2013 Aug; 37(8):900-6. PubMed ID: 23623559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Frequency of del(12p) is commonly underestimated in myelodysplastic syndromes: Results from a German diagnostic study in comparison with an international control group.
    Braulke F; Müller-Thomas C; Götze K; Platzbecker U; Germing U; Hofmann WK; Giagounidis AA; Lübbert M; Greenberg PL; Bennett JM; Solé F; Slovak ML; Ohyashiki K; Le Beau MM; Tüchler H; Pfeilstöcker M; Hildebrandt B; Aul C; Stauder R; Valent P; Fonatsch C; Bacher U; Trümper L; Haase D; Schanz J
    Genes Chromosomes Cancer; 2015 Dec; 54(12):809-17. PubMed ID: 26355708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peripheral blood cytogenetics allows treatment monitoring and early identification of treatment failure to lenalidomide in MDS patients: results of the LE-MON-5 trial.
    Braulke F; Schulz X; Germing U; Schuler E; Platzbecker U; Nolte F; Hofmann WK; Giagounidis A; Götze K; Lübbert M; Schlenk RF; Schanz J; Bacher U; Ganser A; Büsche G; Letsch A; Schafhausen P; Bug G; Brümmendorf TH; Haas R; Trümper L; Shirneshan K; Haase D
    Ann Hematol; 2017 Jun; 96(6):887-894. PubMed ID: 28374162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Usefulness of classic cytogenetic testing compared to fluorescence in situ hybridization in genetic diagnosis of 58 patients with myelodysplastic syndromes.
    Skonieczka K; Duszeńko E; Wyrowińska E; Haus O
    Pol Arch Med Wewn; 2009 Jun; 119(6):366-72. PubMed ID: 19694218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Cytogenetic characteristics of hematopoietic and stromal progenitor cells in myelodysplastic syndrome].
    Pimenova MA; Parovichnikova EN; Kokhno AV; Domracheva EV; Manakova TE; Mal'tseva IuS; Konnova ML; Shishigina LA; Savchenko VG
    Ter Arkh; 2013; 85(7):34-42. PubMed ID: 24137945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM).
    Della Porta MG; Tuechler H; Malcovati L; Schanz J; Sanz G; Garcia-Manero G; Solé F; Bennett JM; Bowen D; Fenaux P; Dreyfus F; Kantarjian H; Kuendgen A; Levis A; Cermak J; Fonatsch C; Le Beau MM; Slovak ML; Krieger O; Luebbert M; Maciejewski J; Magalhaes SM; Miyazaki Y; Pfeilstöcker M; Sekeres MA; Sperr WR; Stauder R; Tauro S; Valent P; Vallespi T; van de Loosdrecht AA; Germing U; Haase D; Greenberg PL; Cazzola M
    Leukemia; 2015 Jul; 29(7):1502-13. PubMed ID: 25721895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FISH analysis of circulating CD34+ cells as a new tool for genetic monitoring in MDS: verification of the method and application to 27 MDS patients.
    Braulke F; Schanz J; Jung K; Shirneshan K; Schulte K; Schuetze C; Steffens R; Trümper L; Haase D
    Leuk Res; 2010 Oct; 34(10):1296-301. PubMed ID: 20226527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of the revised International Prognostic Scoring System, cytogenetics and monosomal karyotype on outcome after allogeneic stem cell transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia evolving from myelodysplastic syndromes: a retrospective multicenter study of the European Society of Blood and Marrow Transplantation.
    Koenecke C; Göhring G; de Wreede LC; van Biezen A; Scheid C; Volin L; Maertens J; Finke J; Schaap N; Robin M; Passweg J; Cornelissen J; Beelen D; Heuser M; de Witte T; Kröger N;
    Haematologica; 2015 Mar; 100(3):400-8. PubMed ID: 25552702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytogenetic features and prognosis analysis in Chinese patients with myelodysplastic syndrome: a multicenter study.
    Wang H; Wang X; Xu X; Lin G
    Ann Hematol; 2010 Jun; 89(6):535-44. PubMed ID: 19921190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantity of clonal cells detected by conventional cytogenetic analysis correlates with bone marrow blasts and survival in myelodysplastic syndromes.
    Kim M; Chung S; See CJ; Yoon SS; Kim BK; Kim HK; Lee DS
    Leuk Res; 2012 Feb; 36(2):163-8. PubMed ID: 21920602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone Marrow Conventional Karyotyping and Fluorescence In Situ Hybridization:  Defining an Effective Utilization Strategy for Evaluation of Myelodysplastic Syndromes.
    He R; Wiktor AE; Durnick DK; Kurtin PJ; Van Dyke DL; Tefferi A; Patnaik MS; Ketterling RP; Hanson CA
    Am J Clin Pathol; 2016 Jul; 146(1):86-94. PubMed ID: 27353768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monitoring of the Clonal Fraction by Fluorescence In Situ Hybridization in Myelodysplastic Syndrome: Comparison With International Working Group Treatment Response Criteria.
    Park JH; Kim M; Kong SY; Yoon SS; Lee DS
    Arch Pathol Lab Med; 2016 Jun; 140(6):560-9. PubMed ID: 27232348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Standardized fluorescence in situ hybridization testing based on an appropriate panel of probes more effectively identifies common cytogenetic abnormalities in myelodysplastic syndromes than conventional cytogenetic analysis: a multicenter prospective study of 2302 patients in China.
    Lai YY; Huang XJ; Li J; Zou P; Xu ZF; Sun H; Shao ZH; Zhou DB; Chen FP; Liu ZG; Zhu HL; Wu DP; Wang C; Zhang Y; Li Y; Hou M; Du X; Wang X; Li W; Lai YR; Zhou J; Zhou YH; Fang MY; Qiu L; Wang XM; Zhang GS; Jiang M; Liang YM; Zhang LS; Chen XQ; Bai H; Lin JY
    Leuk Res; 2015 May; 39(5):530-5. PubMed ID: 25823643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic classification of MDS is improved by the inclusion of FISH panel testing with conventional cytogenetics.
    Kokate P; Dalvi R; Koppaka N; Mandava S
    Cancer Genet; 2017 Oct; 216-217():120-127. PubMed ID: 29025586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Coalesced multicentric analysis of 2,351 patients with myelodysplastic syndromes indicates an underestimation of poor-risk cytogenetics of myelodysplastic syndromes in the international prognostic scoring system.
    Schanz J; Steidl C; Fonatsch C; Pfeilstöcker M; Nösslinger T; Tuechler H; Valent P; Hildebrandt B; Giagounidis A; Aul C; Lübbert M; Stauder R; Krieger O; Garcia-Manero G; Kantarjian H; Germing U; Haase D; Estey E
    J Clin Oncol; 2011 May; 29(15):1963-70. PubMed ID: 21519021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Diagnosis and prognosis in myelodysplastic syndromes. The impact of cytogenetics].
    Mecucci C
    Recenti Prog Med; 2014 Mar; 105(3):110-4. PubMed ID: 24675452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Additional prognostic value of bone marrow histology in patients subclassified according to the International Prognostic Scoring System for myelodysplastic syndromes.
    Verburgh E; Achten R; Maes B; Hagemeijer A; Boogaerts M; De Wolf-Peeters C; Verhoef G
    J Clin Oncol; 2003 Jan; 21(2):273-82. PubMed ID: 12525519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge.
    Schanz J; Tüchler H; Solé F; Mallo M; Luño E; Cervera J; Granada I; Hildebrandt B; Slovak ML; Ohyashiki K; Steidl C; Fonatsch C; Pfeilstöcker M; Nösslinger T; Valent P; Giagounidis A; Aul C; Lübbert M; Stauder R; Krieger O; Garcia-Manero G; Faderl S; Pierce S; Le Beau MM; Bennett JM; Greenberg P; Germing U; Haase D
    J Clin Oncol; 2012 Mar; 30(8):820-9. PubMed ID: 22331955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. International scoring system for evaluating prognosis in myelodysplastic syndromes.
    Greenberg P; Cox C; LeBeau MM; Fenaux P; Morel P; Sanz G; Sanz M; Vallespi T; Hamblin T; Oscier D; Ohyashiki K; Toyama K; Aul C; Mufti G; Bennett J
    Blood; 1997 Mar; 89(6):2079-88. PubMed ID: 9058730
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.